Cytokine release syndrome and CAR T Cell therapy: Modulating the intensity of the inflammatory response and resolution within the tumor microenvironment
CAR T cell therapy achieves high degrees of success with respect to complete response and overall response rates in many hematological cancers, especially lymphomas. Compared to other immunotherapies, these “activated” blood products are plagued by a high incidence of a severe systemic inflammatory...
Saved in:
| Main Authors: | David F. Driscoll, Bruce R. Bistrian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1615526/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion
by: Shufeng Xie, et al.
Published: (2025-03-01) -
In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
by: Anett Pfeiffer, et al.
Published: (2018-09-01) -
An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies
by: Alexander Mazein, et al.
Published: (2025-08-01) -
Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation
by: Beatriz Perucha, et al.
Published: (2025-10-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)